Basal Cell Carcinoma
197
23
39
103
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
33 trials with published results (17%)
Research Maturity
103 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.1%
10 terminated out of 197 trials
91.2%
+4.6% vs benchmark
8%
16 trials in Phase 3/4
32%
33 of 103 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 103 completed trials
Clinical Trials (197)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Basal Cell Carcinoma Chemoprevention Trial
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
Intraoperative Confocal Laser Scanning Microscopy With Use of AI for Optimized Surgical Excision of Basal Cell Carcinoma
Impact of Dysport on PMFF Donor Scar
Study to Examine Lesions of the Skin Using Confocal Laser Microscopy
Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
A Study of Observation and Follow-up in People With Basal Cell Carcinoma
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer